DiaCarta Receives Grant To Validate RadioTherapy Efficacy Tests
DiaCarta, a San Francisco-Nanjing molecular diagnostics compnay, received a $300,000 grant from the National Cancer Institute to validate its RadTox QuantiDNATM product as a test for monitoring radiation response in cancer patients. Currently, no reliable methodology exists for assessing a patient's response to radiotherapy. The QuantiDNATM will be used to monitor circulating free DNA (cfDNA), a patented DNA biomarker, directly from patient plasma during radiation therapy. In 2014, DiaCarta raised $8 million in a Series A Round funding from BVCF (BioVeda China).